Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18 F-FDG-PET

Abstract

Background

We evaluated the potential of diffusion-weighted MRI (DW-MRI) and ¹⁸F-FDG-PET for the early prediction of a triple negative breast cancer (TNBC) response to cisplatin.

Methods

Cisplatin-treated TNBC tumor-bearing mice were categorized as responders or non-responders based on the tumor growth rate. DW-MRI and ¹⁸F-FDG-PET were performed before and after treatment (day 0 and days 3 and 7, respectively). The average apparent diffusion coefficient value (ADC_mean), the highest standardized uptake value (SUV_max), and the metabolic tumor volume (MTV) were measured. The ratios of each parameter relative to day 0 were calculated [ΔADC_mean (day 3) and (day 7), ΔSUV_max (day 3) and (day 7), and ΔMTV (day 3) and (day 7), respectively]. Overall survival rates were compared based on the thresholds determined by these parameters.

Results

Both the day 3 and day 7 ratios of ADC_mean and MTV showed significant differences between the responder and non-responder groups, whereas the ratios of SUV_max did not. Mice with ΔADC_mean (day 3) exceeding the threshold showed a longer overall survival rate. Mice with ΔSUV_max (day 7), ΔMTV (day 3), and ΔMTV (day 7) below the respective thresholds showed a longer overall survival rate.

Conclusions

The ratios of ADC_mean, SUV_max, and MTV have the potential to predict the therapeutic response and to screen non-responders in the ultra-early phase following cisplatin treatment in patients with TNBC.

http://ift.tt/2G4AbZX